Literature DB >> 20606125

Factors associated with adverse outcomes in outpatients presenting with pulmonary embolism: the Worcester Venous Thromboembolism Study.

Frederick A Spencer1, Robert J Goldberg, Darleen Lessard, George Reed, Cathy Emery, Joel M Gore, Luigi Pacifico, Jeff I Weitz.   

Abstract

BACKGROUND: Data from clinical trials suggest that short-term mortality in outpatients presenting with pulmonary embolism (PE) is low and that outpatient therapy may be appropriate. However, subjects enrolled in these studies may not be representative of patients seen in the community setting. METHODS AND
RESULTS: The medical records of residents from Worcester, Mass, with International Classification of Disease, Ninth Edition, codes consistent with potential venous thromboembolism during 1999, 2001, and 2003 were independently validated and reviewed by trained abstractors. A total of 305 patients presented with PE from the outpatient setting. The rates of recurrent PE, major bleeding, mortality, or occurrence of any 1 of these end points at 90 days were 1.4%, 9.5%, 11.1%, and 20.1%, respectively. Patients with a history of congestive heart failure, recent intensive care unit discharge, cancer, severe infection, systolic blood pressure <100 mm Hg, and male sex were at increased risk for the composite end point.
CONCLUSIONS: In the present population-based study, morbidity and mortality after outpatient PE were much higher than what was observed in clinical studies. Our findings raise questions about broad-based outpatient treatment of PE in the community setting. In our study, comorbid conditions and recent illness were important determinants of adverse outcomes, suggesting that these variables should be carefully considered before embarking on outpatient therapy of PE.

Entities:  

Mesh:

Year:  2010        PMID: 20606125      PMCID: PMC3248812          DOI: 10.1161/CIRCOUTCOMES.110.937441

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  14 in total

1.  The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism.

Authors:  Frederick A Spencer; Cathy Emery; Darleen Lessard; Frederick Anderson; Sri Emani; Jayashri Aragam; Richard C Becker; Robert J Goldberg
Journal:  J Gen Intern Med       Date:  2006-07       Impact factor: 5.128

2.  Outpatient treatment of pulmonary embolism with dalteparin.

Authors:  M J Kovacs; D Anderson; B Morrow; L Gray; D Touchie; P S Wells
Journal:  Thromb Haemost       Date:  2000-02       Impact factor: 5.249

3.  Predicting adverse outcome in patients with acute pulmonary embolism: a risk score.

Authors:  J Wicki; A Perrier; T V Perneger; H Bounameaux; A F Junod
Journal:  Thromb Haemost       Date:  2000-10       Impact factor: 5.249

4.  Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection.

Authors:  P S Wells; M J Kovacs; J Bormanis; M A Forgie; D Goudie; B Morrow; J Kovacs
Journal:  Arch Intern Med       Date:  1998-09-14

5.  Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.

Authors:  Clive Kearon; Jeffrey S Ginsberg; Jim A Julian; James Douketis; Susan Solymoss; Paul Ockelford; Sharon Jackson; Alexander G Turpie; Betsy MacKinnon; Jack Hirsh; Michael Gent
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

6.  Derivation and validation of a prognostic model for pulmonary embolism.

Authors:  Drahomir Aujesky; D Scott Obrosky; Roslyn A Stone; Thomas E Auble; Arnaud Perrier; Jacques Cornuz; Pierre-Marie Roy; Michael J Fine
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

7.  Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.

Authors:  M D Silverstein; J A Heit; D N Mohr; T M Petterson; W M O'Fallon; L J Melton
Journal:  Arch Intern Med       Date:  1998-03-23

8.  Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients.

Authors:  J H Beer; M Burger; S Gretener; S Bernard-Bagattini; H Bounameaux
Journal:  J Thromb Haemost       Date:  2003-01       Impact factor: 5.824

9.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

Authors:  H R Büller; B L Davidson; H Decousus; A Gallus; M Gent; F Piovella; M H Prins; G Raskob; A E M van den Berg-Segers; R Cariou; O Leeuwenkamp; A W A Lensing
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

10.  Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with three months of follow-up.

Authors:  C Bova; R Pesavento; A Marchiori; A Palla; I Enea; V Pengo; A Visonà; A Noto; P Prandoni
Journal:  J Thromb Haemost       Date:  2009-03-19       Impact factor: 5.824

View more
  10 in total

1.  Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: The POMPE-C tool.

Authors:  Jeffrey A Kline; Pierre-Marie Roy; Martin P Than; Jackeline Hernandez; D Mark Courtney; Alan E Jones; Andrea Penaloza; Charles V Pollack
Journal:  Thromb Res       Date:  2012-04-03       Impact factor: 3.944

2.  Glomerular Filtration Rate as a Prognostic Factor for Long-Term Mortality after Acute Pulmonary Embolism.

Authors:  Valdis Ģībietis; Dana Kigitoviča; Barbara Vītola; Sintija Strautmane; Andris Skride
Journal:  Med Princ Pract       Date:  2019-02-04       Impact factor: 1.927

Review 3.  The role of molecular imaging in diagnosis of deep vein thrombosis.

Authors:  Sina Houshmand; Ali Salavati; Søren Hess; Mudalsha Ravina; Abass Alavi
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-08-15

Review 4.  AF and Venous Thromboembolism - Pathophysiology, Risk Assessment and CHADS-VASc score.

Authors:  Nasir Shariff; Abdul Aleem; Mukesh Singh; Yuan Z Li; Stacey J Smith
Journal:  J Atr Fibrillation       Date:  2012-10-06

5.  Population health, outcomes research, and prevention: example of the American Heart Association 2020 goals.

Authors:  Véronique L Roger; Christopher J O'Donnell
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-01

6.  Cirrhosis is Associated with an Increased 30-Day Mortality After Venous Thromboembolism.

Authors:  Kirstine Kobberøe Søgaard; Erzsébet Horváth-Puhó; Jonathan Montomoli; Hendrik Vilstrup; Henrik Toft Sørensen
Journal:  Clin Transl Gastroenterol       Date:  2015-07-02       Impact factor: 4.488

7.  In-hospital and short-term predictors of mortality in patients with intermediate-high risk pulmonary embolism.

Authors:  Gulay Gök; Mehmet Karadağ; Tufan Çinar; Zekeriya Nurkalem; Dursun Duman
Journal:  J Cardiovasc Thorac Res       Date:  2020-11-28

8.  Modulation of soluble guanylate cyclase ameliorates pulmonary hypertension in a rat model of chronic thromboembolic pulmonary hypertension by stimulating angiogenesis.

Authors:  John Zagorski; Evandro Neto-Neves; Nathan J Alves; Amanda J Fisher; Jeffrey A Kline
Journal:  Physiol Rep       Date:  2022-01

9.  Risk Factors for Lower Limb Deep Vein Thrombosis in Patients With Single-Level Lumbar Fusion: A Prospective Study of 710 Cases.

Authors:  Chun-Ming Zhao; Yu Zhang; Si-Dong Yang; Ai-Bing Huang; Zong-Min Liang; Jian Wu; Qian Chen
Journal:  Clin Appl Thromb Hemost       Date:  2018-09-10       Impact factor: 2.389

10.  Predictive value of heart failure with reduced versus preserved ejection fraction for outcome in pulmonary embolism.

Authors:  Slobodan Obradovic; Boris Dzudovic; Bojana Subotic; Jovan Matijasevic; Zorica Mladenovic; Aleksandar Bokan; Jadranka Trobok; Sandra Pekovic; Sonja Salinger-Martinovic; Ljiljana Jovanovic; Ljiljana Kos; Tamara Kovacevic-Preradovic; Maja Nikolic; Vladimir Miloradovic; Ana Kovacevic-Kuzmanovic; Nenad Zec; Natasa Markovic-Nikolic; Ilija Srdanovic; Zoran Gluvic; Srdjan Kafedzic; Sasa Pancevacki; Aleksandar Neskovic; Stavros Konstantinides
Journal:  ESC Heart Fail       Date:  2020-09-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.